Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Diagnostic cancer genome sequencing and the contribution of germline variants.

Kilpivaara O, Aaltonen LA.

Science. 2013 Mar 29;339(6127):1559-62. doi: 10.1126/science.1233899. Review.

PMID:
23539595
2.

ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.

Paglia LL, Laugé A, Weber J, Champ J, Cavaciuti E, Russo A, Viovy JL, Stoppa-Lyonnet D.

Breast Cancer Res Treat. 2010 Jan;119(2):443-52. doi: 10.1007/s10549-009-0396-z. Epub 2009 Apr 29.

PMID:
19404735
3.

Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.

Kontorovich T, Cohen Y, Nir U, Friedman E.

Breast Cancer Res Treat. 2009 Jul;116(1):195-200. doi: 10.1007/s10549-008-0121-3. Epub 2008 Jul 19.

PMID:
18642075
4.

Ten genes for inherited breast cancer.

Walsh T, King MC.

Cancer Cell. 2007 Feb;11(2):103-5.

5.

Contribution of mutations in ATM to breast cancer development in the Czech population.

Soukupova J, Dundr P, Kleibl Z, Pohlreich P.

Oncol Rep. 2008 Jun;19(6):1505-10.

PMID:
18497957
6.

Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.

Graña B, Fachal L, Darder E, Balmaña J, Ramón Y Cajal T, Blanco I, Torres A, Lázaro C, Diez O, Alonso C, Santamariña M, Velasco A, Teulé A, Lasa A, Blanco A, Izquierdo A, Borràs J, Gutiérrez-Enríquez S, Vega A, Brunet J.

Breast Cancer Res Treat. 2011 Jul;128(2):573-9. doi: 10.1007/s10549-011-1462-x. Epub 2011 Mar 29.

PMID:
21445571
7.

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.

Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J.

BMC Cancer. 2006 Sep 29;6:230.

8.

ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.

Brunet J, Gutiérrez-Enríquez S, Torres A, Bérez V, Sanjosé S, Galceran J, Izquierdo A, Menéndez JA, Gumà J, Borràs J.

Clin Genet. 2008 May;73(5):465-73. doi: 10.1111/j.1399-0004.2008.00987.x. Epub 2008 Apr 2.

PMID:
18384426
9.

Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.

Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ.

Breast Cancer Res. 2007;9(2):R26.

10.

ATM mutations in Finnish breast cancer patients.

Allinen M, Launonen V, Laake K, Jansen L, Huusko P, Kääriäinen H, Børresen-Dale AL, Winqvist R.

J Med Genet. 2002 Mar;39(3):192-6. No abstract available.

11.

Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients.

Keller G, Vogelsang H, Becker I, Plaschke S, Ott K, Suriano G, Mateus AR, Seruca R, Biedermann K, Huntsman D, Döring C, Holinski-Feder E, Neutzling A, Siewert JR, Höfler H.

J Med Genet. 2004 Jun;41(6):e89. No abstract available.

12.

Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer.

Plevova P, Walczyskova S, Jeziskova I, Jurckova N, Krepelova A, Puchmajerova A, Pavlikova K, Foretova L, Zapletalova J, Silhanova E.

Neoplasma. 2009;56(6):500-7.

PMID:
19728758
13.

Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.

Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J.

Mol Oncol. 2008 Dec;2(4):296-316. doi: 10.1016/j.molonc.2008.09.007. Epub 2008 Oct 7.

14.

ATM variants and cancer risk in breast cancer patients from Southern Finland.

Tommiska J, Jansen L, Kilpivaara O, Edvardsen H, Kristensen V, Tamminen A, Aittomäki K, Blomqvist C, Børresen-Dale AL, Nevanlinna H.

BMC Cancer. 2006 Aug 16;6:209.

15.

Histopathological features of breast cancer in carriers of ATM gene variants.

Balleine RL, Murali R, Bilous AM, Farshid G, Waring P, Provan P, Byth K, Thorne H; kConFab Investigators, Kirk JA.

Histopathology. 2006 Nov;49(5):523-32.

PMID:
17064299
16.

Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.

Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, McCormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J.

Hum Mol Genet. 2007 May 1;16(9):1051-7. Epub 2007 Mar 6.

17.

The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants.

Hall J.

Cancer Lett. 2005 Sep 28;227(2):105-14. Epub 2005 Jan 8. Review.

PMID:
16112413
18.

Multi-center screening of mutations in the ATM gene among women with breast cancer - the WECARE Study.

Berstein JL, Concannon P, Langholz B, Thompson WD, Bernstein L, Stovall M, Thomas DC; WECARE Study Collaborative Group.

Radiat Res. 2005 Jun;163(6):698-9. No abstract available.

PMID:
16044499
19.

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ.

Am J Hum Genet. 2000 Feb;66(2):494-500.

20.

ATM polymorphism and hereditary nonpolyposis colorectal cancer (HNPCC) age of onset (United States).

Jones JS, Gu X, Lynch PM, Rodriguez-Bigas M, Amos CI, Frazier ML.

Cancer Causes Control. 2005 Aug;16(6):749-53.

PMID:
16049814
Items per page

Supplemental Content

Write to the Help Desk